Biotechs Slide on Genentech's FDA Woes
The Nasdaq Biotech Index (NBI) slid more than 1% by the end of trading on Monday spurred by the news that the FDA has requested from data on Avastin breast cancer study from bioech giant Genentech (DNA).
DNA slid more than 4% after the FDA requested an independant review of patient scans for progression-free survival, the primary endpoint of the E2100 trial investigating the use of Avastin/Chemotherapy combination therapy in metastatic breast cancer.
Merril Lynch now expects the final FDA approval for E2100 to occur during the first half of 2008, not the first half of 2007 as previously predicted.
While david-sized Oscient Pharmaceuticals (OSCI) on the other hand gained almost 5% to end trading at $1.14 in anticipation of September 12th meeting of the Advisory Panel to the FDA regarding the company's application for Factive to be approved for acute sinus infections.
The Nasdaq Biotech Index (NBI) slid more than 1% by the end of trading on Monday spurred by the news that the FDA has requested from data on Avastin breast cancer study from bioech giant Genentech (DNA).
DNA slid more than 4% after the FDA requested an independant review of patient scans for progression-free survival, the primary endpoint of the E2100 trial investigating the use of Avastin/Chemotherapy combination therapy in metastatic breast cancer.
Merril Lynch now expects the final FDA approval for E2100 to occur during the first half of 2008, not the first half of 2007 as previously predicted.
While david-sized Oscient Pharmaceuticals (OSCI) on the other hand gained almost 5% to end trading at $1.14 in anticipation of September 12th meeting of the Advisory Panel to the FDA regarding the company's application for Factive to be approved for acute sinus infections.
posted by Nico at
8:51 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home